News : Novartis

6th January 2012 - Northumberland farmer Lewis Forster has won a trailer worth more than £5,000 after entering a competition organised by Novartis Animal Health and Farmers Weekly.
The Ifor William TA501 livestock trailer was first prize in the competition for sheep farmers who used, or were likely to use, the wormer Zolvix.

Mr Forster, who farms 1,200 acres with 1,200 ewes between Hexham and Allendale, said...

· A group of vets is working to control bovine viral diarrhoea in 30 Northumberland farms

· Move is a response to launch of Scotland’s BVD eradication programme, but will bring benefits to herd health in the north east

· Scheme co-sponsored by Novartis Animal Health
Frimley, 16th December 2011 – A group of Northumberland vets are working with 30 farmers to control bovine viral diarrhoea in response to the...

Frimley, 20.09.11 – Novartis Animal Health is inviting vets and SQPs to take part in a series of CPD (Continued Professional Development) meetings that will provide an update on the major parasites of importance in cattle.
The meetings will take place at locations around the country in October and feature two talks. The first will be ‘Cattle Ectoparasites: What’s New and Important?’ and the second talk will be...

Novartis Animal Health has launched a 0.5L pack for the sheep anti-worm product Zolvix® to make the it more readily available for quarantine dosing, and for the smaller sheep farmer.
Zolvix is a broad spectrum product that has the ability to kill all common sheep worms, including those resistant to existing treatments. As such, it has a key role to play in quarantine treatment to keep parasite infection down to...

A product used to treat sheep infested with ticks has had its status upgraded, meaning one treatment will now treat ticks for up to 10 weeks.
Crovect®, which is produced by Novartis Animal Health, also works in the treatment and control of headflies, the treatment of biting lice, and the prevention and treatment of blowfly strike in sheep.

With the extended claim, Crovect® is now a good choice for long lasting...

Uppsala, February 17, 2010

Orexo AB (publ) –
Year-end Report January–December 2009



Key events during the year
• Net revenues totaled MSEK 236.1 (233.3).
• The loss after tax was MSEK 98.1 (loss: 103.1).
• The loss per share amounted to a loss of SEK 4.32 (loss: 4.77).
• Cash and cash equivalents at year-end totaled MSEK 87.4 (188.2).
• Abstral was launched in UK, Germany, France, Spain and Greece.
• In March,...

Uppsala, November 10, 2009

Orexo AB (publ) – Interim report January-September 2009


Key events during the period
• Net revenues amounted to MSEK 208.2 (141.2).
• The loss after tax was MSEK 40.1 (loss: 88,6).
• The loss per share was SEK 1.78 (loss: 4.10).
• Cash and cash equivalents at the end of the quarter totaled MSEK 107.1 (195.7).
• In March, the US Food and Drug Administration (FDA) approved Orexo’s Edluar...

Uppsala, Sweden, 28 August, 2009 - Orexo (STO: ORX) announces it has signed an exclusive worldwide licensing agreement with a Novartis affiliate to develop and commercialise a novel product related to Orexo’s OX17 program.

Under the terms of the agreement, Novartis will fund all future development of the new product and will receive an exclusive license to all related intellectual property. Orexo will receive...